pixantrone + fludarabine + cytarabine + methotrexate + granulocyte-colony stimulating factor

This regimen is an experimental multi-agent chemotherapy and supportive care combination comprising pixantrone, fludarabine, cytarabine, methotrexate, and a granulocyte‑colony stimulating factor (G‑CSF). Pixantrone is a novel aza‑anthracenedione antitumor antibiotic designed to intercalate DNA and inhibit topoisomerase II with reduced cardiotoxicity compared with traditional anthracyclines, and has demonstrated antitumor activity in leukemia and lymphoma models.[17][19] Fludarabine is a purine nucleoside analog that inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, thereby impairing DNA synthesis and repair, and is often combined with cytarabine to potentiate cytarabine triphosphate accumulation in leukemic cells.[2] Cytarabine is a pyrimidine antimetabolite that is phosphorylated intracellularly to ara‑CTP and incorporated into DNA, leading to chain termination and inhibition of DNA synthesis.[2] Methotrexate is a folate analog that primarily inhibits dihydrofolate reductase, depleting reduced folates needed for thymidylate and purine synthesis, and at high doses is used in lymphoma and CNS‑directed therapy.[10] G‑CSF (typically filgrastim or a related agent) is a recombinant growth factor that binds the granulocyte colony‑stimulating factor receptor on hematopoietic progenitors to stimulate neutrophil proliferation, differentiation, and release, used here to mitigate severe chemotherapy‑induced neutropenia and maintain dose intensity.[3][9][18][20] Overall, the combination is conceptually aimed at heavily pretreated or refractory hematologic malignancies, exploiting multiple, complementary antimetabolite and topoisomerase II–directed mechanisms while using G‑CSF support to reduce infectious complications.